Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
Scholar Rock Holding Corporation (SRRK)
Last scholar rock holding corporation earnings: 11/12 07:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
- SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA) - Pharmacodynamic results from the completed multiple-ascending dose portion of the trial show robust and durable target engagement by SRK-015 - Final results from the Phase 1 trial will be presented at the upcoming Cure SMA Annual Conference CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced positive final top-line results from the Phase 1 clinical trial of its product candidate, SRK-015, a highly specific inhibitor of myostatin activation, in healthy adult volunteers. Consistent with previously announced interim findings, the final results showed robust and sustained target engagement and no appar
Show less
Read more
Impact Snapshot
Event Time:
SRRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRRK alerts
High impacting Scholar Rock Holding Corporation news events
Weekly update
A roundup of the hottest topics
SRRK
News
- China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug [Yahoo! Finance]Yahoo! Finance
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
- Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at HC Wainwright from $35.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Scholar Rock GAAP EPS of -$0.66 misses by $0.06 Nov. 12, 2024 7:28 AM ET By: Meghavi Singh , SA News Editor [Seeking Alpha]Seeking Alpha
SRRK
Earnings
- 11/12/24 - Miss
SRRK
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- SRRK's page on the SEC website